| Publisher's Note: Today's newsletter was delayed due to an unexpected issue with our web platforms. The newsletter will be delivered at its usual time on Monday. |
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.
|
|
Today’s Big NewsJan 26, 2024 |
| By Max Bayer,Gabrielle Masson Coming off one of the worst years for IPOs in recent history, two new upsized IPOs have offered a stretching ray of hope that 2024 may not be so bad after all. |
|
|
|
By James Waldron Consider that IPO window well and truly opened. The day after CG Oncology became the first biotech to join the Nasdaq in 2024, ArriVent BioPharma has now followed suit with its own upsized offering. |
By Gabrielle Masson Bristol Myers Squibb is proving its worth as an M&A competitor, coming out on top not once but twice in terms of fresh acquisitions. Most recently, the pharma’s $4.1 billion bid for radiopharmaceuticals biotech RayzeBio was enough to beat out two other companies that also put down offers. |
Sponsored by Cardinal Health Cell and gene therapy patients often require support throughout their treatment journey. Learn key considerations for developing patient support programs. |
By Nick Paul Taylor Formosa Pharmaceuticals has handed over another set of regional rights to its near-approval eye drug candidate APP13007, striking a deal that positions Cristália Produtos Químicos Farmacêuticos to bring the product to market in Brazil. |
By Nick Paul Taylor The European Medicines Agency (EMA) has swatted away Minoryx Therapeutics’ attempt to bring a rare disease drug candidate to market on the strength of a clinical trial that missed its primary endpoint. But, undeterred, Minoryx and partner Neuraxpharm are seeking a re-examination of the regulatory rejection. |
By Helen Floersh Silo Therapeutics’ ketamine-based drug for Alzheimer’s dementia is effective at alleviating some of the condition’s psychological and behavioral symptoms in mice, according to the company. |
By Max Bayer,Andrea Park,Gabrielle Masson Apnimed is bringing on Pfizer's head of migraine market to be chief commercial officer. Lilly's EVP of global quality is set to retire after 34 years. Cerevel's head of commercial joins Neumora following AbbVie sale. |
By Ayla Ellison While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. |
By Angus Liu The combination of Merck's Keytruda and Pfizer and Astellas' Padcev recently made waves in bladder cancer—and the broader oncology world—by delivering a massive life-extension benefit. Now, Merck can claim another positive readout for Keytruda in bladder cancer, although this one is short of a home run. |
By Andrea Park The violations were outlined in U.S. Department of Transportation documents obtained in a records request by the Physicians Committee of Responsible Medicine—an animal research advocacy group that has previously claimed that Neuralink mistreats its animal subjects, in accusations that Neuralink has denied. |
By Angus Liu The FDA will convene an advisory committee to discuss Johnson & Johnson and Legend's Carvykti filing in earlier multiple myeloma. AstraZeneca has won a world-first approval for its rare blood disorder add-on therapy in Japan. Samsung Biologics tallied an “exceptional” year in 2023. And more. |
Fierce podcastsDon’t miss an episode |
| | While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. |
|
|---|
|
|
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.
|
|
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
